Assessing Treatment Options and Improving Utilization for Spinal Muscular Atrophy: Basil Darras, MD
July 28th 2022The associate neurologist-in-chief at Boston Children’s Hospital provided insight on the treatment decisions clinicians make for patients with SMA and the challenges with improving optimization. [WATCH TIME: 3 minutes]
Prescribed Hypnotic Medications, Not Insomnia Diagnosis, Cause Increased Risk for Serious Falls
July 28th 2022Findings showed that, although risk for serious fall injury was not mitigated by insomnia diagnosis, individuals with active insomnia taking prescribed hypnotic medication may be a particularly high-risk subgroup.
Institutional Perspectives in Neurology, Chaired by Annette Okai, MD
July 27th 2022Chaired by Annette Okai, MD, of North Texas Institute of Neurology & Headache, the presentations also feature Fernando Cuascut, MD, MPH, of Baylor College of Medicine; and Lauren Tardo, MD, and Rebecca Romero, MD, of UT Southwestern Medical Center. [WATCH TIME: 1 hour, 18 minutes]
Functional Capacity May Predict Treatment Response to Cognitive Rehabilitation in Multiple Sclerosis
July 26th 2022Using a backward logistic regression model, lower functional capacity between the default-mode network and ventral attention network accurately predicted response to cognitive rehabilitation among a cohort of patients with MS.
Prescribing Psychical Activity Regimens in Spinal Muscular Atrophy: Jacqueline Montes, PT, EdD
July 26th 2022The associate professor of rehabilitation and regenerative medicine at Columbia University Medical Center discussed the ways clinicians go about properly prescribing exercise regimens for patients with spinal muscular atrophy. [WATCH TIME: 3 minutes]
Glatiramer Acetate Shows Long-Term Safety, Efficacy, and Better Outcomes With Early Initiation
July 26th 2022At year 5, significantly lower annualized change in EDSS score, lower incidence of confirmed disability worsening, and lower annualized change in FSS pyramidal function were identified in the early initiated treatment group.
Genetic Stroke Risk May Be Offset by Optimal Cardiovascular Health
July 25th 2022Those with an optimal Life's Simple 7 score had roughly a 30% to 43% lower lifetime stroke risk than those with an inadequate Life's Simple 7 categorization, corresponding to almost 6 additional years of stroke-free life.
Increased Self-Managed Digital Application Use Results in Poststroke Benefits
July 22nd 2022For most of the individuals assessed, the rate of improvement was modulated by practice frequency, with significantly greater improvement over time in those who practice 3 to 5 days per week than those who completed 1 day of sessions per week.
European Commission Passes Eladocagene Exuparvovec as First Approved Treatment for AADC Deficiency
July 22nd 2022In previous clinical studies, patients with AADC deficiency treated with the recombinant AAV2-based gene therapy achieved motor milestones, including head control and unassisted sitting.
Tackling the Global Issue of Ancestral Disparities in Alzheimer Disease: Margaret Pericak-Vance, PhD
July 21st 2022The director of the John P. Hussman Institute for Human Genomics at the University of Miami discussed the background behind a new initiative geared towards understanding genetic differences of underrepresented groups. [WATCH TIME: 6 minutes]
FT218 Receives Tentative Approval for EDS, Cataplexy in Adults With Narcolepsy
July 20th 2022Expected to be marketed as Lumryz by Avadel Pharmaceuticals, the extended-release oral suspension sodium oxybate’s final approval is pending the disposition of the REMS patent listed in the FDA’s Orange Book.